Reclassifying contralateral axillary metastasis: survival benefit of aggressive local therapy challenges stage IV designation
{{output}}
Background: Contralateral axillary metastasis (CAM) is currently staged as M1 (stage IV) breast cancer, guiding treatment towards palliative systemic therapy. However, emerging evidence suggests CAM may behave as a locoregional e... ...
